Integrating BRAF/MEK inhibitors into combination therapy for melanoma
Open Access
- 20 January 2009
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 100 (3) , 431-435
- https://doi.org/10.1038/sj.bjc.6604891
Abstract
The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing.Keywords
This publication has 39 references indexed in Scilit:
- Targeting V600EB-Raf and Akt3 Using Nanoliposomal-Small Interfering RNA Inhibits Cutaneous Melanocytic Lesion DevelopmentCancer Research, 2008
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomasMolecular Cancer Therapeutics, 2008
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in MelanomaCancer Research, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced CancersJournal of Clinical Oncology, 2008
- Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma DevelopmentCancer Research, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft TumorsCancer Research, 2007
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002